Detalhe da pesquisa
1.
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Lancet
; 401(10375): 458-469, 2023 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774155
2.
KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results.
J Allergy Clin Immunol
; 149(6): 2034-2042, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086692
3.
Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Clin Exp Allergy
; 52(9): 1059-1070, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278245
4.
Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat.
Clin Transl Allergy
; 13(9): e12288, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37746795
5.
New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.
J Med Chem
; 51(24): 8124-34, 2008 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-19053774
6.
Non-peptide oxytocin agonists.
Bioorg Med Chem Lett
; 14(17): 4585-9, 2004 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-15357997